HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity
HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity
Hanna Lundgren 0 1
Klara Martinsson 1
Karin Cederbrant 0 1
Johan Jirholt 1
Daniel Mucs 1
Katja Madeyski-Bengtson 1
Said Havarinasab 0 1
Per Hultman 0 1
0 Division of Molecular and Immunological Pathology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, LinkoÈping University, OÈ stergoÈtland County Council, LinkoÈping, Sweden, 2 AIR/ Rheumatology Unit, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, LinkoÈping University, OÈ stergoÈtland County Council, LinkoÈping, Sweden , 3 Swetox , Karolinska Institutet, Unit of Toxicology Sciences, SoÈdertaÈlje, Sweden, 4 AstraZeneca R&D, Transgenic center , MoÈlndal , Sweden
1 Editor: Pavel Strnad , Medizinische Fakultat der RWTH Aachen , GERMANY
The oral thrombin inhibitor ximelagatran was withdrawn in the late clinical trial phase because it adversely affected the liver. In approximately 8% of treated patients, druginduced liver injury (DILI) was expressed as transient alanine transaminase (ALT) elevations. No evidence of DILI had been revealed in the pre-clinical in vivo studies. A whole genome scan study performed on the clinical study material identified a strong genetic association between the major histocompatibility complex alleles for human leucocyte antigens (HLA) (HLA-DR7 and HLA-DQ2) and elevated ALT levels in treated patients. An immunemediated pathogenesis was suggested. Here, we evaluated whether HLA transgenic mice models could be used to investigate whether the expression of relevant HLA molecules was enough to reproduce the DILI effects in humans. In silico modelling performed in this study revealed association of both ximelagatran (pro-drug) and melagatran (active drug) to the antigen-presenting groove of the homology modelled HLA-DR7 molecule suggesting ªaltered repertoireº as a key initiating event driving development of DILI in humans. Transgenic mouse strains (tgms) expressing HLA of serotype HLA-DR7 (HLA-DRB1*0701, -DRA*0102), and HLA-DQ2 (HLA-DQB1*0202,±DQA1*0201) were created. These two lines were crossed with a human (h)CD4 transgenic line, generating the two tgms DR7xhCD4 and DQ2xhCD4. To investigate whether the DILI effects observed in humans could be reproduced in tgms, the mice were treated for 28 days with ximelagatran. Results revealed no signs of DILI when biomarkers for liver toxicity were measured and histopathology was evaluated. In the ximelagatran case, presence of relevant HLA-expression in a preclinical model did not fulfil the prerequisite for reproducing DILI observed in patients. Nonetheless, for the first time an HLA-transgenic mouse model has been investigated for use in HLA-associated DILI induced by a low molecular weight compound. This study shows that mimicking of genetic susceptibility, expressed as DILI-associated HLA-types in mice, is not sufficient for reproducing the complex pathogenesis leading to DILI in man.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
Funding: The funder of this study AstraZeneca
provided support in the form of salaries for authors
(HL, KC, KM, JJ, KMB) but did not have any
additional role in the study design, data collection
and analysis, decision to publish, or preparation of
the manuscript. The specific roles of these authors
are articulated in the author contributions section.
Attritions in late drug development phase are extremely costly and one of the most unwanted
outcomes for pharmaceutical companies. Drug-induced liver injury (DILI) is a major cause
for pharmaceuticals being withdrawn post marketing [
] and belongs to one of the most
common safety issues in preclinical studies [
]. Ximelagatran, a direct thrombin inhibitor
marketed as Exanta™ and launched in Europe in 2004 [
], was developed for the prevention and
treatment of thromboembolic conditions. In long-term clinical studies (>35 days) [
8% of the ximelagatran treated patients had an elevated alanine transaminase (ALT) of >3
times the upper limit of normal (ULN), a level typically observed within the first six months of
]. Elevated ALT levels were also detected after short-term treatment (<35 days),
and ximelagatran was withdrawn in 2006 [
]. No signs of hepatotoxicity could be revealed
during the regular development program nor later in the extended mechanistic investigative in
vitro studies [
] and in vivo studies in mouse, rat, dog, guinea-pig, and cynomolgus monkey
To trace possible adverse outcome pathways (AOPs) and to find relevant biomarkers used
to exclude patients at risk, a number of problem-solving studies (genomics, metabolomics,
proteomics transcriptomics, ligand fishing, and more) were initiated. Most interestingly, a
whole genome scan study [
] showed significant correlations between increased levels of
ALT and presence of the highly variable major histocompatibility complex (MHC) class II
alleles human leucocyte antigen (HLA)-DRB1 07 (odds ratio 4.4 [95% CI 2.2±8.9]) and
HLA-DQA1 02 (odds ratio 4.4 [CI 2.2±8.8]) in affected patients. Expressed in 15% of
European Americans [
], HLA-DRB1 07 and HLA-DQA1 02 are strongly linked and practically
co-inherited. The available data [
] reveal that the two alleles appear to be equally important.
Associations between genetic sequences and either efficacy or safety of drugs at odds ratios
>3.0 (equivalent to >300% increased efficacy or safety) has been suggested to be useful in
clinical practice [
Recently, a growing number of HLA-linked adverse drug reactions that involve small
molecule drugs have been published [15±19]. Finding associations between specific HLA alleles and
increased susceptibility to DILI, Flucloxacillin [
] and Diclofenac , and the possibility
of using HLA-typing in risk management, e.g., HLA-B 57:01 for avoiding Abacavir
hypersensitivity [15,23±25], are important steps forward in understanding the key events leading to
immune-mediated adverse drug-reactions. The haplotype of interest±
HLA-DQA1 02-HLA-DRB1 0701 ±has been associated with DILI [
]. Our hypothesis
involves ximelagatran acting as an inducer of immune-mediated DILI driven by the ªaltered
repertoireº hypothesis  and in silico-modelling has been used to investigate possible
drugassociations with DR7.
This study generates a new pre-clinical model using low molecular weight (LMW) drug
development where drug recognition by specific HLA-alleles is the key initiating event and
AOP leading to an immune-mediated adverse drug effect. We constructed two transgenic
mouse strains (tgms)±DR7 (HLA-DRB1 0701, -DRA 0102) and DQ2 (HLA-DQB1 0202,
DQA1 0201)±that were further crossed with mice expressing human (h)CD4 to create two
double tgms: DR7xhCD4 and DQ2xhCD4. These strains were then characterized by immune
phenotypic and functional tests and subsequently exposed orally to ximelagatran in a 28-day
The high-mobility group protein B1 (HMGB1), used as an inflammatory and necrosis
indicator in vitro [
] and as a hepatotoxicity marker in humans , was included as a
biomarker for hepatotoxicity together with soluble colony-stimulating factor 1 receptor (CSF1R).
Elevated plasma levels of CSF1R were earlier detected in patients with ALT-elevations after
2 / 16
ximelagatran treatment [
]. Glutamate dehydrogenase (GLDH) was also analyzed as yet
another hepatotoxicity marker since it has a higher sensitivity and specificity than ALT [
In summary, the biomarkers HMGB1, CSF1R, GLDH and ALT, together with
histopathological evaluations, were used to look for possible translation between DILI in humans and a
potential DILI in HLA-expressing tgms after ximelagatran exposure.
Materials and methods
During all studies, male and female mice between 7- and 16-weeks old were tested, bred, and
maintained in the animal department at AstraZeneca R&D in SoÈdertaÈlje and MoÈlndal, Sweden.
The animal experiments were approved by Stockholm South region ethics committee
(Sweden). Animals were multiple-housed under pathogen-free conditions, observed once or twice
daily, fed standard chow (RM1 (E) SQC pelleted, Special Diets Services Ltd., England), and
provided tap water ad libitum. Blood samples were taken and final bleeding made under
isoflurane anesthesia. No significant difference in mean weight between groups could be seen
during any phase of the study. The wild type (wt) strain used was C57Bl/6NCrl.
Generation of tgms
We generated two separate double transgenic mouse lines expressing the human MHC of
serotypes HLA-DR7 and HLA-DQ2. The transgenic mouse lines were built to express the MHC
class II α and β cDNAs, each under the control of a separate mouse H2-Eα promoter and
followed by a β-globin poly adenylation signal sequence, both from the plasmid pDOI5 (kindly
provided by Dr. Benoist) [
]. The HLA-DR7 transgene expressed the alleles
HLA-DRA1 0102 and HLA-DRB1 0701, and the HLA-DQ2 transgene expressed the alleles
HLA-DQA1 0201 and HLA-DQB1 0202. To minimize dysregulation and/or integration
effects, each expression unit was flanked by double 1.2 kb insulator, a CTCF binding site
derived from the chicken beta globin locus [
]. Both of these mouse lines were subsequently
crossed onto a hCD4 expressing mouse line. The hCD4 expressing mouse was produced
through random integration of a 42.5kb fragment of a human BAC clone (RPCI-11 101F21),
resulting in the insertion of the fragment Chr12:6888111±6930612 (according to the GRCh37/
hg19 assembly). The fragment contains 21.2 kb sequence upstream of the translational start
and the human CD4 exon and intron structure, including the untranslated regions. After
crossing the lines, two double transgenic mouse lines±DR7xhCD4 and DQ2xhCD4 ±were
Characterization of tgms
Genotyping. Genotypes were determined by PCR amplification of genomic DNA derived
from mouse ear biopsies using the following primers: H2Ea Forw; 5’-ATTCTGGCTGGCGT
GGAAAT-3’, DQA Rev; 5’-AGACAGATGAGGGTGTTGGG-3’, DQB Rev; 5’-CTGGAAGGT
CCAGTCACCAT-3’, DRA Rev; 5’-AGCATCAAACTCCCAGTGCT-3’, DRB Rev; 5’-TGT
CCTCCAGGATGTCCTTC-3’, CD4 Forw; 5’-GCACCACTTTCTTTCCCTGA-3’ and CD4
Rev; 5’-CCCAGCCTAGTATATGCCCA-3’. The PCR products were run on a 0.8% agarose
gel. Animals were used as heterozygotes for all transgenic (tg) constructs.
Phenotyping and verification of HLA and hCD4 expression. Flow cytometric (FACS)
immunophenotyping and control of the expression of HLA-DR7, HLA-DQ2, and hCD4 was
performed on peripheral blood mononuclear cells (PBMC) and spleen cells from tgms,
DR7xhCD4 (n = 5), DQ2xhCD4 (n = 2), and wt (n = 5) animals. For the FACS analysis,
3 / 16
spleens were collected and transferred to RPMI 1640 medium (Gibco) supplied with 10mM
HEPES, 4mM L-glutamine, and 10% fetal calf serum (Gibco). Spleens were single cell
suspended using Medimachine™ (BD Biosciences), washed, and labelled with antibodies
according to manufacturer's instructions. Blood samples were treated with FACS™ lysing solution
(BD, USA) and incubated for five minutes at room temperature (RT) followed by antibody
labelling. The following mAbs were used: anti-mouse (m)CD3, anti-mCD4, anti-mCD8a,
antimCD19, anti-mCD49b, anti-human (h)HLA-DR (clone: G46-6 (L243) [
(clone Tu 169), anti-hCD4 (RPA-T4) (all from BD, Pharmingen, USA), and anti-mMHC class
II (I-A/I-E) (eBioscience, USA). All samples were analyzed the day of sampling on a
FACSCanto II (Becton Dickinson, USA).
Immune function with KLH immunization
A functional immune response was verified by immunizing tgms and wt mice with KLH, a
highly effective T-cell-dependent carrier protein that induces MHC class I and II restricted
immune responses. Five DR7xhCD4 tgm and five wt mice were twice (14 days apart)
intravenously immunized in the tail vein with KLH diluted in PBS (900μg/animal). Blood samples
were taken from orbital plexus before first immunization and at the final bleeding five days
after the second immunization. Serum was prepared and stored at -70ÊC until analyzed for
anti-KLH specific IgG and IgM titres by ELISA (Life Diagnostics, USA) according to the
manufacturer's instructions. All samples were analyzed on the same day.
Ximelagatran exposure of tgms and markers of liver injury
To study the ability of the tgms to mimic the hepatotoxic response seen in humans after
ximelagatran exposure, wt and tg mice were dosed daily via gavage for 28 days with ximelagatran
(120μmol/kg/day). The selected dose for the mice was chosen from the regulatory 28-day
study performed with ximelagatran since it caused maximal pharmacologic effect without
causing adverse bleeding effects. As an example, dosing to humans in one of the clinical trials
was 24 mg (0.72μmol/kg/day) [
]. Ximelagatran administered orally is rapidly transformed to
melagatran, its active form, and the bioavailability is 5 to 10% in rats and about 20% in humans
with low between-subject variation [
]. The effect of tgm DR7 (not expressing hCD4) was
used to investigate possible differences with and without presence of hCD4. Blood samples
were collected the day before start of dosing (day -1), half way through the dosing (day 14),
and at the termination of dosing (day 29) (Table 1). ALT levels in plasma were analyzed on the
day of sampling (Cobas C 501, Roche Diagnostics, USA), and plasma samples for analysis of
CSF1R, HMGB1 and GLDH were stored at -70ÊC and analyzed after the study. Presence of
CSF1R in plasma was analyzed by ELISA. Briefly, plates were coated over night with
antimouse CSF1R monoclonal antibody (R&D Systems, Abingdon, UK,2ug/ml). After washing
4 / 16
and blocking, diluted samples (1/50) were added in duplicate and incubated (2h). Following
washing, biotinylated anti-mouse CSF1R (R&D Systems) was added as a detection antibody.
After incubation and washing, streptavidin/HRP conjugate and stop solution was added (R&D
Systems, USA) and the plate was read using SpectramaxPlus microplate reader (450 nm)
(Molecular Devices). All samples were analyzed on the same day. Recombinant mouse CSF1R
(R&D Systems) was used as a positive control. Presence of GLDH in plasma was analyzed by
ELISA according to the manufacturer (Nordic BioSite, Sweden, number EKM21150).
Liver specimens from left and median lobe were collected at termination. HMGB1
expression was analyzed by RT-PCR using liver samples frozen in RNAlater™ (Qiagen, Santa Clarita,
CA). mRNA was isolated using Rneasy Mini kit (Qiagen) and translated to cDNA using High
Capacity cDNA RT kit (Applied biosystems, Foster City, CA). The samples were run on
Applied Biosystems 7900HT (Applied Biosystems) using a standard protocol, and fold change
(before vs. after treatment) was calculated. Gross liver pathology and histopathology was
performed on all animals. The paraffin embedded tissue was stained with hematoxylin and eosin
(HE stain) and periodic acid-Schiff (PAS).
In silico modelling
Possible associations of ximelagatran (pro-drug) and melagatran (active drug) to the
antigenpresenting groove of DR7 were investigated. First, the complete structure of HLA-DR7 was
created using the UniProt BLAST algorithm [
], the identity was 92,1% between the β-chain
of HLA-DR1 (UniProt ID: P04229) and HLA-DR7 (UniProt ID: P13761) after alignment. Due
to this high sequence identity between the two chains, it was possible to create a HLA-DR7
model using the sequence of HLA-DR7 and an existing crystal structure of HLA-DR1 [
with the homology modelling tool Prime [
]. Once the homology model of the HLA-DR7
βchain was created, it was merged with the α-chain of HLA-DR1 structure to create a complete
unit. Second, binding-site identification was performed on this complex using the SiteMap
], with successfully identified the antigen-binding groove as a potential binding site
With the information gathering from SiteMap, ligand-target molecular docking
experiments were performed with Glide [
] using melagatran and ximelagatran as the ligands.
Statistical analyses of ex vivo data
The nonparametric Kruskal-Wallis test was used for statistical comparisons between
unmatched groups. If a significant difference between three or more groups was detected,
Mann-Whitney test was used to compare the distributions of two unmatched groups.
Characterization of the tgms
Phenotyping of lymphocytes and verification of HLA and hCD4 expression.
The proportion of lymphoid cell sub-populations from blood and spleen were compared
between the tgms (DR7xhCD4 and DQ2xhCD4) and wt littermates to explore possible
differences due to the insertion of human genes. The tgms showed similar proportions of total
Tand NK-cell numbers compared to wt mice. However, significant differences between wt and
tgms DR7xhCD4 mice could be seen; that is, DR7xhCD4 mice had fewer CD8+ T-cells in both
spleen and PBMC, more mCD4+ T-cells in spleen, and fewer CD19+ cells in PBMC (Fig 2).
The expression of hCD4 and HLA-DR/DQ on tgms compared to wt can be seen in Fig 3.
5 / 16
Fig 1. Identified antigen-binding groove binding-site. Antigen-binding groove binding-site identification of
homology modelled HLA-DR7 using SiteMap (A±front view, B±top view). Blue±hydrogen bond donor region,
red±hydrogen bond acceptor region, yellow±hydrophobic region, white±binding site grid.
6 / 16
Fig 2. Verification of normal and comparable profiles between wt and tg mice. Representation of lymphoid cell subsets
from PBMC (A) and spleen (B) to compare wt and tg mice using mouse specific tracer antibodies. */** significant difference,
* p 0.05 ** p 0.01.
The introduction of hCD4 into the mouse genome resulted in significantly higher amount
of hCD4+ T-cells in tgms compared with mCD4+ T-cells in wt mice in the PBMC population.
In spleen population, the amount of hCD4+ T-cells in tgms was significantly lower than the
mCD4+ T-cell population (Table 2). In PBMC of tgms, virtually all cells expressing mCD4 also
expressed hCD4 (Fig 3).
Tgms had fewer HLA+ B-cells compared to H2+ B-cells in wt mice. For DR7xhCD4 it was
40% (PBMC) and 23% (spleen) and for DQ2xhCD4 it was 47% (PBMC) fewer (Table 2).
7 / 16
Fig 3. Representative surface-marker expression on cells from wt and tg mice. A and B illustrate the
expression surface markers hCD4 and HLA DR/DQ on PBMCs, respectively. C displays the T-cell population and
shows that hCD4 in the tgms is almost exclusively expressed on T-cells also expressing mCD4.
Percent of surface markers in the lymphoid cell populations from PBMC and spleen in tg- and wt-animals.
*/** significant difference compared to wt, * p 0.05 ** p 0.01
Immune function with KLH immunization
To verify normal in vivo immune function post HLA-insertion, strain DR7xhCD4 was
immunized with KLH and the results compared to corresponding antibody responses in wt mice. All
animals which were immunized with KLH responded with a distinct KLH-IgG and KLH-IgM
specific response, and no statistical differences in titers of KLH-specific IgG- and
IgMresponses were observed (S1 Fig).
Ximelagatran exposure of tgms and markers of liver injury
Daily oral ximelagatran exposure for 28 days showed no significant differences in group mean
values of plasma ALT pre- and post-treatment in either wt mice or tgms (Fig 4). All values
before and after treatment, with respect to sex and age, were within the 95% normal interval.
Correspondingly, no significant differences were noted in group mean values of CSF1R levels
between pre- and post-treated wt and tgms (S2 Fig). In addition, no significant difference was
observed in mRNA expression of HMGB1 (S3 Fig) or levels of GLDH from plasma samples
pre-study, day 14 and day 28 (S4 Fig) when comparing wt animals and tgms. Also, no
significant difference was observed with regard to any macroscopic or histopathological changes in
the liver of wt mice and tgms following ximelagatran treatment. No significant difference in
any of the analyzed biomarkers could be when comparing tgms with or without hCD4
In silico modelling
Both ximelagatran (pro-drug) and melagatran (active drug) are predicted to bind to the
antigen-binding groove of HLA-DR7 in a similar location (Fig 5). However, the orientation of the
best docked poses (from the docking score values calculated by Glide) differ between the two
compounds. The reason behind this difference will be investigated in future in silico studies.
To our knowledge, this is the first study that evaluates whether HLA tgms can be used to
predict DILI in humans following LMW drug treatment. Unlike many other HLA-transgenic
models developed for use in the pharmaceutical industry [45±47], our system did not
constitute a disease model for studying drug effects. Instead, we wanted to develop a safety model to
investigate whether the tgms could imitate the liver effect seen in humans after ximelagatran
treatment and be used in risk assessment.
Immunophenotyping of the lymphoid cell populations of produced tgms showed
significant differences between wt and tgms. However, they were not considered to be of any
biological relevance. Immunization with KLH did not indicate any significant difference in immune
function between tgms and wt littermates.
For the first time, in silico-modelling studies revealed that both the pro-drug ximelagatran
and the active drug melagatran have the capacity to associate to the antigen-binding groove of
HLA-DR7. This new information importantly strengthens the hypothesis of these
low-molecular entities having potential capacity to induce an ªaltered repertoireº driven immune response
After ximelagatran treatment, no macroscopic or histopathological changes in the liver or
signals from any of the tested biomarkers for liver injury (ALT, CSF1R, HMGB1, or GLDH)
indicated any adverse liver reaction in either wt or tgms. Thus, none of our tgms responded to
ximelagatran exposure as observed in humans exposed to ximelagatran.
9 / 16
Fig 4. ALT levels in animals treated with ximelagatran for 28 days. ALT levels in mice compared before
and after 28 days of ximelagatran treatment. A fold change of one equals no change between start of
treatment and end of treatment; fold change of two equals two times higher ALT levels.
Given our hypothesis that HLA-DR7 and/or HLA-DQ2 are necessary to initiate events
leading to DILI from ximelagatran exposure, the sole presence of these receptors in another
species was not enough to reproduce the adverse response observed in human. How can this
Possible limitations for using HLA as a stand-alone denominator for addressing and predicting DILI
DILI development. The fact that DILI only develops in a small fraction of patients, even
though the fraction is higher if patients carry the genetic susceptibility, makes the phenomena
difficult to study. The number of animals in our studies could therefore have been too low to
capture the development of DILI, even though individual differences between laboratory mice
likely is less than between humans carrying a common genetic susceptibility marker.
HLA expression. The number of HLA positive cells and the HLA expression level could
be an important factor and a possible limitation with our models. The expression of HLA-DR7
and HLA-DQ2 on B-cells was between 22 and 47% lower on tgms than the almost 100%
expression of H2 on B-cells from wt mice. In humans, HLA-DR7 and HLA-DQ2 positive
individuals express these alleles on all MHC-expressing cells. Thus, the relatively lower number of
HLA-expressing cells could in our models reduce sensitivity to the drug. In our models the
tgms still have the endogenous H2 complex intact. To amplify the contribution from HLA a
H2 knockout mouse [
] could have been used to enhance the interaction between HLA and
hCD4 with reduced possible interference of H2.
Genetic haplotype. Could the absence of DILI in our ximelagatran-treated tgms also be
explained by the requirement of another genetic predisposition for developing DILI and could
this be influenced by the haplotype involving genes other than HLA. One example is induced
T-cell receptor repertoires playing an important part in autoimmune conditions [
Autoimmune hepatitis and DILI have common denominators and distinctions can be scarce.
10 / 16
Fig 5. Structures of drug in HLA-DR7 model. Docked structure of melagatran (A±brown) and ximelagatran
(B±blue) in the antigen-binding groove of the homology modelled HLA-DR7.
11 / 16
Ximelagatran-specific T-cell receptors from DILI-patients were not previously characterized
and could therefore not be included in the current tgms.
Interaction between HLA and CD4. The sequence homology between human CD4 and
mouse CD4 is about 80% for the intra cellular domain but only 55% for the extra cellular
]. Both HLA-DQ [
] and HLA-DR  tgms can respond to specific antigens
in an HLA-restricted manner both with and without hCD4. However, conceivably different
HLA class II alleles or even different T-cell receptor/peptide/MHC complexes may have
different CD4 requirements. Previous studies with HLA tgms have either used mice that are
speciesmatched interaction with CD4 or mice that lack this interaction. Since both systems generate
HLA-restricted responses [
], the importance of the requirement for species-matched
CD4 remains unclear, even though we think a species-matched CD4 is an important factor for
Other conditions correlated to DILI. Conditions other than the presence of specific
HLA may be needed for these models to predict DILI [
]. Earlier studies investigating the
adverse effects seen after exposure to ximelagatran have proposed low nutritional status with
low pyruvate levels [
], gender, and age [
] as potential risk factors for ximelagatran induced
hepatotoxicity in humans. These three risk factors have been investigated in calorie restricted
wt mice dosed with ximelagatran (Park BK et al, University of Liverpool, unpublished
observation) without being able to establish a correlation.
Further, breaking of immune-tolerance in our model might have been yet another
possibility to induce DILI by ximelagatran, allowing drug-specific lymphocytes to be activated.
In conclusion, ximelagatran did not induce any signs of liver injury in any of the two tgms
we constructed with the purpose of establishing a new safety model. Nevertheless, for the first
time, the use of a HLA tg mouse model for prediction of HLA-associated DILI from a LMW
drug has been evaluated. To particularly notice, for the first time we demonstrated that
ximelagatran and melagatran are able to associate with HLA-DR7 obtained by in silico modelling.
S1 Fig. Levels of KLH specific antibodies. Expression of KLH specific IgG (A) and IgM (B)
antibodies before and after immunization with KLH.
S2 Fig. CSF1R in ximelagatran treated mice. CSF1R in plasma before (day-1), during (day
14), and after (day 29) 28 days of ximelagatran treatment.
S3 Fig. Levels of HMGB1 mRNA expression before and after ximelagatran treatment for
28 days. Fold change of HMGB1 mRNA expression between start of treatment (day -1) and
after end of treatment (day 29). A fold change of one demonstrate no treatment effect.
S4 Fig. Levels of GLDH after 28 days of ximelagatran treatment. Levels of GLDH in serum
samples from wild type (wt) and tgms (HLA-DRxhCD4 and HLA-DQxhCD4) mice. Samples
are taken before (day -1), during (day 14), and after (day 29) 28 days of ximelagatran
12 / 16
This work was financed by AstraZeneca R&D as part of the safety problem-solving activities
initiated for ximelagatran (Exanta1). The plasmid Pdoi5 was a kind gift from Dr C. Benoist.
The pathology readings were kindly carried out by pathologist Frank Seeliger at AstraZeneca
Safety Assessment (Sweden) and all the blood and tissue samplings were carried out by the
staff from the AstraZeneca animal department (SoÈdertaÈlje, Sweden).
Conceptualization: Karin Cederbrant, Johan Jirholt.
Formal analysis: Hanna Lundgren, Klara Martinsson, Katja Madeyski-Bengtson, Said
Funding acquisition: Karin Cederbrant.
Investigation: Hanna Lundgren, Klara Martinsson, Karin Cederbrant.
Methodology: Hanna Lundgren, Klara Martinsson, Karin Cederbrant, Johan Jirholt, Daniel
Project administration: Hanna Lundgren.
Resources: Karin Cederbrant, Johan Jirholt.
Supervision: Karin Cederbrant, Per Hultman.
Validation: Hanna Lundgren, Klara Martinsson, Daniel Mucs.
Visualization: Hanna Lundgren, Daniel Mucs.
Writing ± original draft: Hanna Lundgren.
Writing ± review & editing: Karin Cederbrant, Per Hultman.
13 / 16
14 / 16
15 / 16
1. Lee WM ( 2003 ) Drug-induced hepatotoxicity . N Engl J Med 349 : 474 ± 485 . https://doi.org/10.1056/ NEJMra021844 PMID: 12890847
2. Cook D , Brown D , Alexander R , March R , Morgan P , et al. ( 2014 ) Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework . Nat Rev Drug Discov 13 : 419 ± 431 . https:// doi.org/10.1038/nrd4309 PMID: 24833294
3. Albers GW , Diener HC , Frison L , Grind M , Nevinson M , et al. ( 2005 ) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial . JAMA 293 : 690± 698 . https:// doi.org/10.1001/jama.293.6.690 PMID: 15701910
4. Petersen P , Grind M , Adler J , Investigators SI ( 2003 ) Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study . J Am Coll Cardiol 41 : 1445 ± 1451 . PMID: 12742279
5. Lee WM , Larrey D , Olsson R , Lewis JH , Keisu M , et al. ( 2005 ) Hepatic findings in long-term clinical trials of ximelagatran . Drug Saf 28 : 351 ± 370 . PMID: 15783243
6. Agnelli G , Eriksson BI , Cohen AT , Bergqvist D , Dahl OE , et al. ( 2009 ) Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran . Thromb Res 123 : 488 ± 497 . https:// doi.org/10.1016/j.thromres. 2008 . 02 .017 PMID: 18485453
7. European Medicines Agency Press office E ( 2006 ) Press release AstraZeneca withdraws its application for Ximelagatran 36-mg film coated tablets . http://www.ema.europa.eu/docs/en_GB/document_library/ Press_release/ 2010 /02/WC500074073.pdf.
8. Southworth H ( 2014 ) Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran . Stat Med 33 : 2914 ± 2923 . https://doi.org/10.1002/sim.6142 PMID: 24623062
9. Kenne K , Skanberg I , Glinghammar B , Berson A , Pessayre D , et al. ( 2008 ) Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran . Toxicol In Vitro 22 : 730 ± 746 . https://doi.org/10.1016/j.tiv. 2007 . 11 .014 PMID: 18191936
10. Keisu M , Andersson TB ( 2010 ) Drug-induced liver injury in humans: the case of ximelagatran . Handb Exp Pharmacol: 407 ± 418 . https://doi.org/10.1007/978-3- 642 -00663-0_13 PMID: 20020269
11. Kindmark A , Jawaid A , Harbron CG , Barratt BJ , Bengtsson OF , et al. ( 2008 ) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis . Pharmacogenomics J 8 : 186 ± 195 . https://doi.org/10.1038/sj.tpj. 6500458 PMID: 17505501
12. Klitz W , Maiers M , Spellman S , Baxter-Lowe LA , Schmeckpeper B , et al. ( 2003 ) New HLA haplotype frequency reference standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans . Tissue Antigens 62 : 296 ± 307 . PMID: 12974796
13. Harper AR , Topol EJ ( 2012 ) Pharmacogenomics in clinical practice and drug development . Nat Biotechnol 30 : 1117 ± 1124 . https://doi.org/10.1038/nbt.2424 PMID: 23138311
14. Singer JB , Lewitzky S , Leroy E , Yang F , Zhao X , et al. ( 2010 ) A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury . Nat Genet 42 : 711 ± 714 . https://doi.org/10.1038/ ng.632 PMID: 20639878
15. Illing PT , Vivian JP , Dudek NL , Kostenko L , Chen Z , et al. ( 2012 ) Immune self-reactivity triggered by drug-modified HLA-peptide repertoire . Nature 486 : 554 ± 558 . https://doi.org/10.1038/nature11147 PMID: 22722860
16. Yip VL , Alfirevic A , Pirmohamed M ( 2015 ) Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review . Clin Rev Allergy Immunol 48 : 165 ± 175 . https://doi.org/10.1007/ s12016-014-8418-y PMID: 24777842
17. Karlin E , Phillips E ( 2014 ) Genotyping for severe drug hypersensitivity . Curr Allergy Asthma Rep 14 : 418 . https://doi.org/10.1007/s11882-013 -0418-0 PMID: 24429903
18. Pavlos R , Mallal S , Phillips E ( 2012 ) HLA and pharmacogenetics of drug hypersensitivity . Pharmacogenomics 13 : 1285 ± 1306 . https://doi.org/10.2217/pgs.12.108 PMID: 22920398
19. Alfirevic A , Gonzalez-Galarza F , Bell C , Martinsson K , Platt V , et al. ( 2012 ) In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers . Genome Med 4 : 51 . https://doi.org/10.1186/gm350 PMID: 22732016
20. Daly AK , Donaldson PT , Bhatnagar P , Shen Y , Pe'er I , et al. ( 2009 ) HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin . Nat Genet 41 : 816 ± 819 . https://doi.org/10. 1038/ng.379 PMID: 19483685
21. Monshi MM , Faulkner L , Gibson A , Jenkins RE , Farrell J , et al. ( 2013 ) Human leukocyte antigen (HLA)- B* 57 : 01 - restricted activation of drug-specific T cells provides the immunological basis for flucloxacillininduced liver injury . Hepatology 57 : 727 ± 739 . https://doi.org/10.1002/hep.26077 PMID: 22987284
22. Daly AK , Day CP ( 2009 ) Genetic association studies in drug-induced liver injury . Semin Liver Dis 29 : 400 ± 411 . https://doi.org/10.1055/s-0029-1240009 PMID: 19826974
23. Hughes CA , Foisy MM , Dewhurst N , Higgins N , Robinson L , et al. ( 2008 ) Abacavir hypersensitivity reaction: an update . Ann Pharmacother 42 : 387 ± 396 . https://doi.org/10.1345/aph.1K522 PMID: 18303141
24. Mallal S , Nolan D , Witt C , Masel G , Martin AM , et al. ( 2002 ) Association between presence of HLAB*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir . Lancet 359 : 727 ± 732 . PMID: 11888582
25. Ostrov DA , Grant BJ , Pompeu YA , Sidney J , Harndahl M , et al. ( 2012 ) Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire . Proc Natl Acad Sci U S A 109 : 9959 ± 9964 . https://doi.org/10.1073/pnas.1207934109 PMID: 22645359
26. Sharma SK , Balamurugan A , Saha PK , Pandey RM , Mehra NK ( 2002 ) Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment . Am J Respir Crit Care Med 166 : 916 ± 919 . https://doi.org/10.1164/rccm.2108091 PMID: 12359646
27. Spraggs CF , Parham LR , Hunt CM , Dollery CT ( 2012 ) Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes . Clin Pharmacol Ther 91 : 647 ± 652 . https://doi.org/10. 1038/clpt. 2011 .277 PMID: 22357454
28. Bharadwaj M , Illing P , Theodossis A , Purcell AW , Rossjohn J , et al. ( 2012 ) Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex . Annu Rev Pharmacol Toxicol 52 : 401 ± 431 . https://doi.org/10.1146/annurev-pharmtox- 010611 -134701 PMID: 22017685
29. Martin-Murphy BV , Holt MP , Ju C ( 2010 ) The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice . Toxicol Lett 192 : 387 ± 394 . https://doi.org/10.1016/j.toxlet. 2009 . 11 .016 PMID: 19931603
30. Antoine DJ , Williams DP , Kipar A , Jenkins RE , Regan SL , et al. ( 2009 ) High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo . Toxicol Sci 112 : 521 ± 531 . https://doi.org/10.1093/toxsci/kfp235 PMID: 19783637
31. Zhou RR , Liu HB , Peng JP , Huang Y , Li N , et al. ( 2012 ) High mobility group box chromosomal protein 1 in acute-on-chronic liver failure patients and mice with ConA-induced acute liver injury . Exp Mol Pathol 93 : 213 ± 219 . https://doi.org/10.1016/j.yexmp. 2012 . 05 .006 PMID: 22609241
32. Andersson U , Lindberg J , Wang S , Balasubramanian R , Marcusson-Stahl M , et al. ( 2009 ) A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran . Biomarkers 14 : 572 ± 586 . https://doi.org/10.3109/13547500903261354 PMID: 19780643
33. Robles-Diaz M , Medina-Caliz I , Stephens C , Andrade RJ , Lucena MI ( 2016 ) Biomarkers in DILI: One More Step Forward . Front Pharmacol 7 : 267 . https://doi.org/10.3389/fphar. 2016 .00267 PMID: 27597831
34. Kouskoff V , Fehling HJ , Lemeur M , Benoist C , Mathis D ( 1993 ) A vector driving the expression of foreign cDNAs in the MHC class II-positive cells of transgenic mice . J Immunol Methods 166 : 287 ± 291 . PMID: 7507147
35. Chung JH , Bell AC , Felsenfeld G ( 1997 ) Characterization of the chicken beta-globin insulator . Proc Natl Acad Sci U S A 94 : 575 ± 580 . PMID: 9012826
36. Panina-Bordignon P , Fu XT , Lanzavecchia A , Karr RW ( 1992 ) Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen . J Exp Med 176 : 1779 ± 1784 . PMID: 1460432
37. Eriksson BI , Agnelli G , Cohen AT , Dahl OE , Lassen MR , et al. ( 2003 ) The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study . J Thromb Haemost 1 : 2490 ± 2496 . PMID: 14675083
38. Eriksson UG , Bredberg U , Hoffmann KJ , Thuresson A , Gabrielsson M , et al. ( 2003 ) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans . Drug Metab Dispos 31 : 294 ± 305 . PMID: 12584156
39. Cullberg M , Eriksson UG , Wahlander K , Eriksson H , Schulman S , et al. ( 2005 ) Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis . Clin Pharmacol Ther 77 : 279 ± 290 . PMID: 15903126
40. UniProt C ( 2015 ) UniProt: a hub for protein information . Nucleic Acids Res 43 : D204 ± 212 . https://doi. org/10.1093/nar/gku989 PMID: 25348405
41. Gunther S , Schlundt A , Sticht J , Roske Y , Heinemann U , et al. ( 2010 ) Bidirectional binding of invariant chain peptides to an MHC class II molecule . Proc Natl Acad Sci U S A 107 : 22219 ± 22224 . https://doi. org/10.1073/pnas.1014708107 PMID: 21115828
42. Jacobson MP , Pincus DL , Rapp CS , Day TJ , Honig B , et al. ( 2004 ) A hierarchical approach to all-atom protein loop prediction . Proteins 55 : 351 ± 367 . https://doi.org/10.1002/prot.10613 PMID: 15048827
43. Halgren T ( 2007 ) New method for fast and accurate binding-site identification and analysis . Chem Biol Drug Des 69 : 146 ± 148 . https://doi.org/10.1111/j.1747- 0285 . 2007 . 00483 . x PMID : 17381729
44. Friesner RA , Murphy RB , Repasky MP , Frye LL , Greenwood JR , et al. ( 2006 ) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes . J Med Chem 49 : 6177 ± 6196 . https://doi.org/10.1021/jm051256o PMID: 17034125
45. Luckey D , Bastakoty D , Mangalam AK ( 2011 ) Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice . J Autoimmun 37 : 122 ± 128 . https://doi.org/10. 1016/j.jaut. 2011 . 05 .001 PMID: 21632210
46. Taneja V , David CS ( 2010 ) Role of HLA class II genes in susceptibility/resistance to inflammatory arthritis: studies with humanized mice . Immunol Rev 233 : 62 ± 78 . https://doi.org/10.1111/j.0105- 2896 . 2009 . 00858 . x PMID : 20192993
47. Mangalam AK , Rajagopalan G , Taneja V , David CS ( 2008 ) HLA class II transgenic mice mimic human inflammatory diseases . Adv Immunol 97 : 65 ± 147 . https://doi.org/10.1016/S0065- 2776 ( 08 ) 00002 - 3 PMID: 18501769
48. Madsen L , Labrecque N , Engberg J , Dierich A , Svejgaard A , et al. ( 1999 ) Mice lacking all conventional MHC class II genes . Proc Natl Acad Sci U S A 96 : 10338 ± 10343 . PMID: 10468609
49. Chen Z , de Kauwe AL , Keech C , Wijburg O , Simpfendorfer K , et al. ( 2006 ) Humanized transgenic mice expressing HLA DR4-DQ3 haplotype: reconstitution of phenotype and HLA-restricted T-cell responses . Tissue Antigens 68 : 210 ± 219 . https://doi.org/10.1111/j.1399- 0039 . 2006 . 00656 . x PMID : 16948641
50. Maddon PJ , Molineaux SM , Maddon DE , Zimmerman KA , Godfrey M , et al. ( 1987 ) Structure and expression of the human and mouse T4 genes . Proc Natl Acad Sci U S A 84 : 9155 ± 9159 . PMID: 3501122
51. Yamamoto K , Fukui Y , Esaki Y , Inamitsu T , Sudo T , et al. ( 1994 ) Functional interaction between human histocompatibility leukocyte antigen (HLA) class II and mouse CD4 molecule in antigen recognition by T cells in HLA-DR and DQ transgenic mice . J Exp Med 180 : 165 ± 171 . PMID: 8006580
52. Yeung RS , Penninger JM , Kundig TM , Law Y , Yamamoto K , et al. ( 1994 ) Human CD4-major histocompatibility complex class II (DQw6) transgenic mice in an endogenous CD4/CD8-deficient background: reconstitution of phenotype and human-restricted function . J Exp Med 180 : 1911 ± 1920 . PMID: 7964466
53. Altmann DM , Douek DC , Frater AJ , Hetherington CM , Inoko H , et al. ( 1995 ) The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4 . J Exp Med 181 : 867 ± 875 . PMID: 7532684
54. Sonderstrup G , Cope AP , Patel S , Congia M , Hain N , et al. ( 1999 ) HLA class II transgenic mice: models of the human CD4+ T-cell immune response . Immunol Rev 172 : 335 ± 343 . PMID: 10631958
55. Ulrich RG ( 2007 ) Idiosyncratic toxicity: a convergence of risk factors . Annu Rev Med 58 : 17 ± 34 . https:// doi.org/10.1146/annurev.med. 58 .072905.160823 PMID: 16958561
56. Ford GA , Choy AM , Deedwania P , Karalis DG , Lindholm CJ , et al. ( 2007 ) Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials . Stroke 38 : 2965 ± 2971 . https://doi.org/10.1161/STROKEAHA.107.488007 PMID: 17885258
57. Metushi IG , Hayes MA , Uetrecht J ( 2015 ) Treatment of PD-1(-/-) mice with amodiaquine and antiCTLA4 leads to liver injury similar to idiosyncratic liver injury in patients . Hepatology 61 : 1332 ± 1342 . https://doi.org/10.1002/hep.27549 PMID: 25283142
58. Chakraborty M , Fullerton AM , Semple K , Chea LS , Proctor WR , et al. ( 2015 ) Drug-induced allergic hepatitis develops in mice when myeloid-derived suppressor cells are depleted prior to halothane treatment . Hepatology 62 : 546 ± 557 . https://doi.org/10.1002/hep.27764 PMID: 25712247